Comparative studies of total cross-linking, cell survival and cell cycle perturbations in Chinese hamster cells treated with alkylating agents in vitro.

[1]  J. Hilton.  Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and -resistant L1210 cells. , 1984, Biochemical pharmacology.

[2]  R. Clutterbuck,et al.  Studies on the toxicity of cyclophosphamide in combination with mesna in vitro and in vivo. , 1983, Cancer treatment reviews.

[3]  B. Fox,et al.  DNA-DNA interstrand crosslinking by dimethyanesulphonic acid esters. Correlation with cytotoxicity and antitumour activity in the Yoshida lymphosarcoma model and relationship to chain length. , 1983, Biochemical pharmacology.

[4]  N. Sládek,et al.  Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats. , 1983, Cancer research.

[5]  D. Murray,et al.  Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo. , 1983, British Journal of Cancer.

[6]  R. Ozols,et al.  Chemotherapy in advanced disease , 1982 .

[7]  K. Kohn,et al.  Comparative studies of DNA cross-linking and cytotoxicity in Burkitt's lymphoma cell lines treated with cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. , 1982, Cancer research.

[8]  J. Murnane,et al.  Irreparable DNA cross-links and mammalian cell lethality with bifunctional alkylating agents. , 1981, Chemico-biological interactions.

[9]  K. Kohn,et al.  Cytotoxicity and DNA cross-linking activity of 4-sulfidocyclophosphamides in mouse leukemia cells in vitro. , 1980, Cancer research.

[10]  A. Belch,et al.  L-phenylalanine mustard (melphalan) uptake and cross-linking in the RPMI 6410 human lymphoblastoid cell line. , 1980, Cancer research.

[11]  P. Cox.  Cyclophosphamide cystitis--identification of acrolein as the causative agent. , 1979, Biochemical pharmacology.

[12]  D. Vistica.  Cytotoxicity as an indicator for transport mechanism: evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell. , 1979, Biochimica et biophysica acta.

[13]  E. Wiltshaw,et al.  Remission Induction in Chronic Granulocytic Leukaemia using Intermittent High‐Dose Busulphan , 1978, British journal of haematology.

[14]  K. Kohn,et al.  Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. , 1978, Cancer research.

[15]  C. Fenselau,et al.  Alkylating properties of phosphoramide mustard. , 1976, Cancer research.

[16]  J. Roberts,et al.  DNA repair after mustard gas alkylation by sensitive and resistant Yoshida sarcoma cells in vitro. , 1970, Chemico-biological interactions.

[17]  W. Verly,et al.  The letal action of monofunctional and bifunctional alkylating agents on T7 coliphage. , 1969, Biochimica et biophysica acta.

[18]  P. D. Lawley,et al.  The reaction of mono- and di-functional alkylating agents with nucleic acids. , 1961, The Biochemical journal.

[19]  P. Alexander,et al.  Differences in the response of leukaemia cells in tissue culture to nitrogen mustard and to dimethyl myleran. , 1961, Biochemical pharmacology.

[20]  J. Lett,et al.  The biological significance of the changes produced in the deoxyribonucleic acid of cells treated with radiomimetic alkylating agents. , 1960, Biochemical pharmacology.

[21]  E. Fielden,et al.  Polyfunctional radiosensitizers. I. Effects of a nitroxyl biradical on the survival of mammalian cells in vitro. , 1976, Radiation research.